DavidJVaughnMD
Oncology • Philadelphia, PAGenitourinary Oncology, Hematologic Oncology
Professor of Medicine, University Pennsylvania
Dr. Vaughn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Spruce St
Fl 12
Philadelphia, PA 19104Phone+1 215-662-3914
Summary
- Dr. David Vaughn is an oncologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center. He received his medical degree from Harvard Medical School and has been in practice 30 years. He specializes in genitourinary oncology and hematologic oncology and is experienced in hematologic oncology, prostate cancer, urologic oncology, bladder cancer, and testicular cancer.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1990 - 1993
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1987 - 1990
Harvard Medical SchoolClass of 1987
Certifications & Licensure
NJ State Medical License 2021 - 2025
PA State Medical License 1990 - 2024- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FACP) American College of Physicians, 2005
- Super Doctor SuperDoctors.com
Publications & Presentations
PubMed
- 2266 citationsPembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae-Lyun Lee
The New England Journal of Medicine. 2017-02-17 - 35 citationsEfficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-II...Stephen M. Keefe, Jean H. Hoffman-Censits, Roger B. Cohen, Ronac Mamtani, Daniel F. Heitjan
Annals of Oncology. 2016-08-01 - 48 citationsHigh-dose cytarabine neurotoxicity: MR findings during the acute phase.David J. Vaughn, J G Jarvik, David B. Hackney, S Peters, Edward A. Stadtmauer
AJNR. American Journal of Neuroradiology. 1993-07-01
Other
- Approach to the care of long-term testicular cancer survivorsVaughn DJ, Beard CJ
http://www.uptodate.com/contents/approach-to-the-care-of-long-term-testicular-cancer-survivors
UpToDate, Wolters Kluwer Health - 2012-07-10
Press Mentions
Pembrolizumab Offers Better QOL vs Chemo in Advanced Urothelial CancerApril 9th, 2018
1 in 4 Inmate Deaths Happens in the Same Federal Prison. Why?September 28th, 2023
Committees
- Chair, ABIM Medical Oncology SEP 2013 - 2014
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
